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Introduction
Cardiology and immunology are disciplines born apart, with 
different goals and tenets. Nonetheless, a fertile association 
between these areas of knowledge has recently flourished, and 
leukocytes have now been implicated in the control of cardiac 
metabolism (1), rhythm (2, 3), aging (4), and repair (5–8). The 
contribution of immunological phenomena to cardiac repair is 
of particular clinical relevance, because myocardial infarction 
(MI) is the leading cause of death worldwide (9). In addition to 
causing a life-threatening hemodynamic imbalance, the myocar-
dial injury triggered by ischemia imposes a healing challenge for 
the heart, which is a terminally differentiated organ. Thus, many 
patients who survive an acute MI episode subsequently develop 
chronic heart failure (HF) due to maladaptive myocardial repair 
(10). Hence, there is an unmet need to better understand and 
eventually modulate the immune-inflammatory mechanisms 
underlying the myocardial healing process.
T lymphocytes are major players in the mediation of tissue 
repair, including that following cardiac injury (11–14). The partic-
ipation of T cells in myocardial inflammation and repair has been 
observed in many organisms, ranging from fishes (14) to mammals 
(15–19), indicating that it is an evolutionarily conserved phenom-
enon. Previous studies from our group and others indicated that 
CD4+ T cells become primed and proliferate in the mediastinal 
lymph nodes (med-LNs) (heart-draining LNs) of infarcted mice 
and then infiltrate the myocardium (16, 18, 20, 21). Independent 
groups have reported that the Tregs (defined as FOXP3+) activat-
ed after MI exert salutary effects by accelerating the resolution 
of inflammation and promoting appropriate extracellular matrix 
deposition in the myocardial scar (14, 18, 20, 22, 23). Conventional 
T helper (Tconv) cells (defined as FOXP3–) have also been shown 
to positively influence the molecular milieu in the infarcted myo-
cardium via a mechanism that depends on the extracellular puri-
nergic metabolism (24).
T cell reactivity can benefit myocardial healing in mice by pro-
moting reparative fibrosis in a postmitotic organ. However, sus-
tained T cell responses in the heart can also fuel adverse remod-
eling and contribute to the progression of ischemic HF at later 
chronic stages (19). Furthermore, chronic T cell activation in the 
myocardium has also been shown to be detrimental in experimen-
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shown in Figure 1, A, C, and E, this single MYHCA614–628 peptide 
could recapitulate similar T cell responses in infarcted mice. The 
results revealed no response to a control peptide representing an 
irrelevant antigen (OVA323–339), and we observed no IFN-γ response 
to any of the peptides tested, including MYHCA (Figure 1A).
Cardiac myosin–specific Th cells selectively accumulate in the 
infarcted heart and acquire a regulatory phenotype. After identi-
fying MYHCA614–628 as a crucial cardiac antigen that triggers the 
activation of Th cells in the MI context, we sought to monitor the 
in vivo distribution and activation profile of MYHCA-specific 
T cells in infarcted mice. To that end, we adoptively transferred 
5 × 106 Thy1.1 MYHCA-specific cells into Thy1.2 syngeneic WT 
recipient mice prior to the induction of EMI and monitored the 
distribution and activation profile of these cells by flow cytom-
etry (Figure 2 and Supplemental Figure 1). We obtained these 
cells from a mouse strain exclusively bearing transgenic T cell 
receptors (TCRs) specific for the immunogenic MYHCA peptide 
(MYHCA614–629) presented in the MHC-II context (hereafter 
referred to as TCR-M cells) (33). Monoclonal TCR-M cells were 
defined as CD4+TCRβ+Thy1.1+TCVα2+ singlets. Polyclonal endog-
enous Th cells (ENDO cells) were defined as CD4+TCRβ+Thy1.1– 
singlets. As shown in Figure 2B, TCR-M cells selectively accumu-
lated in the heart and med-LNs of infarcted mice at the peak of 
the wound-healing phase (day 7). The TCR-M cells vanished 
during a later chronic phase, indicating that post-MI autoreactiv-
ity to cardiac myosin is a self-limiting phenomenon (Figure 2C). 
Light-sheet fluorescence microscopy (LSFM) of whole unsliced 
hearts confirmed that TCR-M cells accumulated within the infarct 
zone but not in the healthy remote myocardium (Figure 2, D and 
E, and Supplemental Video 1). The results revealed no antigen- 
specific T cell accumulation on day 49 after MI (Figure 2F).
MI also had a major impact on the differentiation of TCR-M 
cells. When transferred into the MI context, TCR-M cells exhibited 
increased levels of CD44 surface expression at all sites compared 
with baseline (i.e., before transfer) expression levels (Figure 2, G–I). 
The frequency of CD44+ differentiated cells was also higher among 
MI TCR-M cells than in the endogenous CD4+ T cell compartment 
(ENDO cells) at all analyzed sites (P < 0.05). We observed no CD44 
upregulation in the TCR-M cells found in the subiliac LNs (si-LNs) 
of sham-operated mice (Figure 2G). However, the TCR-M cells iso-
lated from the med-LNs of both infarcted and sham-operated mice 
displayed markers of cell activation (Figure 2H). These findings sug-
gest that MYHCA is constitutively presented to CD4+ T cells in the 
heart-draining LNs of healthy mice, even in the absence of cardiac 
damage, as previously reported (21, 34). TCR-M cells were virtually 
absent from sham-operated hearts, but they exhibited a differenti-
ated phenotype in infarcted hearts (Figure 2I). We observed a sim-
ilar pattern for FOXP3 expression. Notably, 55.2% of the TCR-M 
cells in the infarcted hearts were FOXP3+, in sharp contrast to the 
baseline frequency (8.8%).
To better understand the mechanisms underlying the accu-
mulation of FOXP3+ TCR-M cells in the heart, we transferred 
Treg (CD25+, FOXP3+) and Tconv (CD25–, FOXP3–) TCR-M cells 
labeled with distinct, subset-specific fluorescent intracellular trac-
ers (Figure 3A). Flow cytometric analyses performed on day 7 after 
MI confirmed that both T cell subsets strongly proliferated in the 
heart and the med-LNs, but in not the si-LNs, of infarcted mice 
tal models of pressure overload–induced HF and during aging (4, 
25–27). Taken together, these findings indicate that the crosstalk 
between T cells and the heart can result in a broad spectrum of pos-
sible outcomes in mice, depending on the context of activation and 
the timing of these responses. Furthermore, whether post-MI T cell 
responses are driven by cardiac antigens or by the recognition of 
danger-associated molecular patterns in the context of a particu-
lar cytokine milieu has not yet been established. Most important, 
the translational relevance of this heart/T cell axis has not yet been 
fully confirmed in a meaningful clinical setting, mainly due to the 
challenges of obtaining samples from relevant sites other than 
peripheral blood, such as the myocardium and draining LNs (28).
In this study, we sought to elucidate the principles governing T 
cell activation, differentiation, and functionality in the context of 
experimental MI (EMI) and to monitor the distribution of T cells in 
the heart and med-LNs of patients with MI. Through a combination 
of unbiased screening with hypothesis-driven approaches, we iden-
tified an antigen-specific mode of T cell activation and revealed that 
the myocardium imposes an activation context that promotes the 
development of heart-specific T helper (Th) cells poised to exhibit a 
cardioprotective phenotype during the healing stage. Moreover, we 
combined histological analyses of myocardial autopsy samples with 
thoracic PET/CT imaging using the novel radiotracer [68Ga]pen-
tixafor, a ligand for CXCR4, and our results provide strong clinical 
evidence that a heart/T cell axis is also active in MI patients.
Results 
Myosin heavy chain α is a dominant cardiac antigen that triggers Th 
cell activation after EMI. The proteins released by cardiomyocyte 
death during an ischemic event can be a source of antigens that 
stimulate adaptive immune cells. Thus, we sought to verify wheth-
er post-MI CD4+ T cell responses are heart specific and to ultimate-
ly identify relevant cardiac epitopes. We tested the reactivity pro-
file of CD4+ T cells purified from infarcted mice against a library of 
153 peptides covering the 8 most relevant heart-enriched proteins 
encoded by mRNAs with more than 5 levels in the heart compared 
with those in all other tissues, as detailed in the Human Protein 
Atlas (29). The cardiac proteins selected include sarcomere ele-
ments (α actin, cardiac muscle 1 [ACTC1], myosin-binding protein 
C3 [MYBPC3], myosin heavy chain α [MYHCA], myosin light chain 
2 [MYL2], troponin I3, cardiac muscle [TNNI3], and troponin T2, 
cardiac muscle [TNNT2]) , a cardiac receptor (adrenergic receptor 
β 1 [ARB1]), and a mitochondrial component (heat shock protein 
family B3 [HSPB3]). The specific peptides (15 mers) (Supplemen-
tal Table 1; supplemental material available online with this article; 
https://doi.org/10.1172/JCI123859DS1) were selected on the basis 
of in silico simulation of their MHC-II binding properties (30).
As shown in Figure 1, A–E, splenocytes purified from infarct-
ed (but not from sham-operated) mice showed an IL-2 response 
to MYHCA-derived epitopes, which is considered a readout for 
antigen-specific stimulation. No IL-2 response was observed when 
the T cells were challenged with all other tested peptides, reveal-
ing that MYHCA is a dominant cardiac antigen in the MI context. 
This heart-specific myosin isoform has already been implicated in 
the pathogenesis of experimental autoimmune myocarditis, and 
previous studies identified a specific MHC-II–restricted epitope 
(MYHCA614–628) that is relevant in that disease model (31, 32). As 
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contrasting gene expression patterns in response to MI. After MI, 
the ENDO compartment, primarily composed of polyclonal cells, 
showed 236 downregulated genes but only 43 upregulated genes 
(>2-fold difference versus the sham counterpart, P < 0.05). These 
findings reveal that, despite patent inflammation, MI imposes a 
largely inhibitory context on most polyclonal T cells. In sharp con-
trast, the TCR-M cells had 153 upregulated and only 38 downreg-
ulated transcripts in response to MI, confirming that MI promotes 
the stimulation of heart-specific Th cells.
The TCR-M cells activated in the MI context displayed a 
unique gene expression profile enriched with growth factors and 
prohealing mediators, but not with cytokines related to the classi-
cal Th cell subsets. A list of the top 100 regulated transcripts is pro-
vided in Supplemental Figure 2, and the top 30 regulated genes are 
shown in Figure 4C. Enrichment pathway analyses indicated that 
transcripts related to T cell trafficking within LNs (sphingosine 1/
phosphate pathway), the TCR signaling cascade, and responses to 
hypoxic stress were particularly upregulated in TCR-M cells after 
MI (Figure 4D and Supplemental Table 2, P < 0.05). With regard 
to the molecular function of TCR-M cells, unsupervised analy-
ses identified macrophage-CSF (M-CSF) receptor binding, che-
mo kine receptor binding, IL-4 receptor binding, TGF-ß receptor 
binding, IL-1 receptor binding, and growth factor activity among 
the top regulated transcription response patterns in TCR-M cells 
(Figure 3, B–D). These results confirm that post-MI T cell respons-
es are largely driven by MYHCA-derived antigens. Remarkably, 
more than 50% of the TCR-M cells labeled as Tconv prior to cell 
transfer acquired FOXP3+ expression in the myocardium, but not 
in the LNs, indicating that in situ Treg conversion was the major 
factor driving Treg accumulation in the myocardial tissue (Figure 
3B). Myosin-specific T cells also underwent in situ Treg conver-
sion in the absence of MI (Figure 3B), but the numbers of TCR-M 
cells found in the infarcted hearts were typically higher than those 
in sham-operated hearts (Figure 2, B and L). Taken together, these 
results indicate that MI promotes the activation and recruitment 
of heart-specific Th cells and that the myocardial context induces 
myosin-specific T cells to acquire a Treg phenotype.
Antigen-specific Th cells activated in the MI context acquire a 
nonclassical gene expression signature enriched with prohealing fac-
tors. To better characterize how the MI context shapes the dif-
ferentiation of antigen-specific CD4+ T cells, we subsequently 
sorted TCR-M and ENDO cells from the med-LNs of infarcted 
and sham-operated mice (day 7) for downstream gene expression 
profiling (Figure 4 and Supplemental Figure 2).
The TCR-M cells were purified by FACS and defined as 
CD4+TCRβ+Thy1.1+TCVα2+ singlets, whereas the ENDO cells 
were defined as CD4+TCRβ+Thy1.1– singlets. As shown in Figure 
4, A and B, the TCR-M and ENDO cell compartments displayed 
Figure 1. Cardiac epitope mapping. (A) Heatmaps depicting the number of specific T cell responses to defined antigens of interest. Splenocytes puri-
fied from MI or sham-operated mice (day 7) were cultured in the presence of peptide pools (15 mers, MHC-II–restricted) covering the most important 
heart-enriched proteins, and the production of IL-2 and IFN-γ was monitored by ELISPOT as a readout for antigen-specific stimulation. The single peptides 
MYHCA614–628 (included in the MYHCA pool) and OVA323–339 (irrelevant antigen, not expressed in the heart) were also tested. (B and C) Quantification of 
IL-2–producing cells per well in response to (B) the MYHCA peptide pool and (C) MYHCA614–628. (D and E) Representative ELISPOT images of these antigens. 
The number of responder cells found in each well is shown directly next to the representative images. The bar graphs display the group mean values, the 
SEM, and the distribution of each individual value. Statistical analysis was determined with a 2-tailed, unpaired t test (B and C). *P < 0.05. The data were 
acquired from 3 independent experiments.
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that were stimulated after MI selectively showed unregulated 
expression levels of inhibitory checkpoint receptors such as Tigit, 
Pdcd1, Ctla4, and Btla (Figure 4E, P < 0.05). Moreover, these cells 
were particularly enriched with transcripts related to extracellu-
lar purinergic metabolism (Cd38, Nt5e, and Entpd1) and signaling 
(P2rx4 and P2rx7) (Figure 4E). Taken together, transcriptome 
profiling revealed that the MI context imposes an inhibitory tonus 
on polyclonal ENDO cells but favors the development of heart- 
specific T cells with a distinct gene expression profile.
that were activated after MI (Figure 4D, Supplemental Figure 3, 
and Supplemental Table 3, P < 0.05).
Notably, we found that most of the genes related to classically 
polarized Th cells (e.g., Ifng, Tnf, Il13, and Il17) were not differen-
tially expressed in TCR-M cells activated after MI (Supplemental 
Figure 3). Notwithstanding this finding, in response to MI, TCR-M, 
but not ENDO, cells significantly upregulated a unique set of 
growth factors and prohealing mediators, such as Csf1, Angptl2, 
Grn, Tgfb3, and Fgf2 (Figure 4E, P < 0.05). Moreover, TCR-M cells 
Figure 2. TCR-M cells selective-
ly accumulate in the infarcted 
heart. (A) Experimental design 
and gating strategy. Thy1.1 TCR-M 
cells were transferred into Thy1.2 
WT recipients prior to MI or sham 
operations. The contour plots are 
representative of the med-LNs 7 
days after MI. The frequencies of 
TCR-M cells found in the si-LNs, 
med-LNs (heart-draining), and 
heart were assessed on (B) day 
7 and (C) day 49 after MI. The 
accumulation index refers to the 
spleen-normalized frequencies. (D 
and F) 3D reconstruction of infarct-
ed hearts (original magnification, 
×5) on day 7 (D and E) and day 49 
(F) after MI. The morphological 
information was obtained from the 
autofluorescence levels acquired 
in the green channel. The viable 
myocardium appears in bright 
green, and the necrotic myocardi-
um appears in dark green. Scale 
bars: 300 μm. TCR-M cells (Thy1.1+) 
appear in magenta, and the yellow 
dotted lines indicate the infarct 
borders. (G–L) Frequency of CD44+ 
cells (G–I) and FOXP3+ cells (J–L) 
in the ENDO and TCR-M compart-
ments harvested from different 
sites on day 7 after MI. The dotted 
lines indicate the baseline frequen-
cies (pre-transfer) of CD44+ and 
FOXP3+ among TCR-M cells. The 
graphs display the group mean val-
ues (bars), the SEM, and the dis-
tribution of each individual value. 
(B and C) The green and magenta 
bars represent sham-operated and 
infarcted mice, respectively. (G–L) 
The green and magenta bars repre-
sent endogenous CD4+ T cells and 
TCR-M cells, respectively. The data 
were acquired in at least 2 inde-
pendent experiments; MI (n = 7–23 
mice) and sham (n = 3–12 mice). *P 
< 0.05, by 2-way ANOVA followed 
by Sidak’s multiple comparisons 
test. LV, left ventricle; RV, right 
ventricle; ND, not determined.
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Figure 3. In vivo TCR-M conversion to FOXP3+ Tregs. (A) Experimental design and gating strategy. Before adoptive transfer, Thy1.1+ TCR-M cells were 
enriched for Tconv cells (CD25–) and Tregs (CD25+) through magnetic cell sorting and labeled with distinct, subset-specific cell-tracer dyes (CFSE and VIO, 
respectively). Treg and Tconv TCR-M cell populations were mixed at a 1:20 ratio (resembling the physiological condition) and then transferred into Thy1.2 
WT recipients 1 day before MI or sham operation. The flow cytometric plots depict the pre-transfer levels of FOXP3 in each compartment. (B) Analysis of 
Treg conversion from TCR-M cells in si-LNs, med-LNs, and heart tissues from mice 5 days after MI. Converted Tregs are defined as Thy1.1+CFSE+ cells that 
acquired FOXP3 expression after MI, as the CFSE+ cells were FOXP3– prior to cell transfer. (C and D) Proliferation of Tconv TCR-M cells (Thy1.1+CFSE+FOXP3–) 
and Treg TCR-M cells (Thy1.1+VIO+FOXP3+) was assessed through the dilution of CFSE and VIO dyes, respectively. Histograms show the dilution of intracel-
lular fluorescent tracers (CFSE or VIO), indicating the frequency of proliferating cells in each compartment analyzed. **P < 0.01, by 2-way ANOVA followed 
by Tukey’s multiple comparisons test (B); *P < 0.05 and P = 0.06, by 2-tailed, unpaired t test (C and D).
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Figure 4. TCR-M cells activated in the MI context acquire a nonclassical gene expression signature enriched with prohealing factors. Adoptively trans-
ferred TCR-M cells (defined as CD4+TCRβ+Thy1.1+TCVα2+ singlets) and polyclonal endogenous CD4+ ENDO cells (defined as CD4+TCRβ+Thy1.1– singlets) were 
sorted from the med-LNs of infarcted and sham-operated mice 7 days after MI and used for downstream gene expression profiling. (A) Volcano plots 
comparing the gene expression levels of ENDO and TCR-M cells after MI or sham operation. The repressed and induced genes (±2-fold change, P < 0.05) 
are highlighted in green and purple, respectively. (B) Total number of up- and downregulated genes in each T cell subset. (C) Top 30 differentially expressed 
genes (MI vs. sham, P < 0.05) in each T cell subset. (D) Unsupervised pathway enrichment analyses and gene clustering according to molecular function 
(TCR-M subset). The bar lengths indicate the adjusted P values (Fisher’s exact test). (E) Normalized relative expression levels (MI vs. sham) of specific 
gene sets related to T cell activation (checkpoint receptors), tissue repair, and purinergic metabolism. The color scale represents the normalized gene 
expression levels (MI vs. sham) in ENDO and TCR-M cells. Data for MI (n = 5) and sham (n = 3) were acquired from 1 experiment.
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Heart-specific CD4+ T cells activated in the MI context exert car-
dioprotective effects. Next, we evaluated the post-MI inflamma-
tion and repair processes in mice receiving adoptive transfer of 
MYHCA- or OVA-specific Th cells (TCR-M and DO11.10 cells, 
respectively) (Figure 5A). We used OVA-specific T cells as a 
control, because OVA is not an autoantigen in mice and hence 
irrelevant in the MI context. In these experiments, we designat-
ed DO11.10 mice as the recipients (35) for the sake of excluding 
any possible effects of endogenous antigen-specific Th cells. The 
specificity of the transferred CD4+ T cells had no impact on infarct 
size (Figure 5B, day 7 after MI), heart–to–body weight ratio, wet 
and dry lung–to–body weight ratio, or absolute numbers of car-
diac leukocytes (Supplemental Figure 4, A–C, day 5 after MI). 
However, echocardiographic analyses performed on day 7 after 
MI revealed that hearts enriched with autoreactive CD4+ T cells 
had a better-preserved fractional area change (FAC), which serves 
as a readout for improved systolic function (Figure 5C, P < 0.05). 
We obtained similar results for the end-systolic area (ESA) mea-
surement (Figure 5D, P = 0.074), but not for the end-diastolic area 
(EDA) measurement (Figure 5E). Mechanistically, we found that 
the adoptive transfer of TCR-M cells promoted an increased accu-
mulation of profibrotic MHC-IIhiCCR2lo macrophages (36) on day 
5 after MI (Figure 5F and Supplemental Figure 4E), compared with 
DO11.10 cell treatment. Histological analyses of the infarct zone 
revealed a higher collagen content in the scars of TCR-M–treat-
ed mice, as quantified by Picrosirius red staining and collagen III 
immunofluorescence staining (Figure 5, G and H, P < 0.05).
To complement this approach, we also transferred WT lym-
phocytes purified from the med-LNs of sham versus infarcted mice 
into lymphocyte-deficient animals and then monitored cardiac 
function in the recipients (Supplemental Figure 5). These exper-
iments were performed because previous studies in the context 
of autoimmune myocarditis have established that the transfer of 
T cells from diseased mice can produce cardiac injury in unchal-
lenged recipients (34). In contrast to the autoimmune myocarditis 
context, we observed no signs of myocardial injury mediated by the 
lymphocytes obtained from infarcted donors (Supplemental Figure 
5, B–E). These findings further support the notion that post-MI T 
cell autoimmunity is not pathogenic during the early healing phase.
CD4+ T cells infiltrating the murine infarcted myocardium exhibit 
a distinct repertoire signature. After showing that T cells specific for 
a prototypic myocardial antigen promote myocardial healing via 
an adoptive transfer approach, we aimed to further confirm wheth-
er the endogenous T cell response is autoantigen dependent. The 
fundamental role of T cells in adaptive immunity relies mainly on 
a diverse repertoire of TCRα and -β chains that display unique anti-
gen specificities. Thus, we performed high-throughput sequencing 
of the TCRβ complementary determining region 3 (CDR3β) on 
FACS-purified CD4+ T cells from the heart and med-LNs of infarct-
ed and sham-operated mice (Figure 6A and Supplemental Figure 
6A) as an unbiased approach to screen for MI-related TCR signa-
tures. As shown in Figure 6, B–D, the CD4+ T cells infiltrating the 
infarcted myocardium exhibited a skewed repertoire dominated 
by a restricted set of TCR sequences. In the tree maps presented 
in Figure 6B, each colored spot represents a unique TCRβ CDR3 
sequence (a T cell clone), and the size of each spot denotes its rela-
tive frequency. The unevenness of the spots observed in the cardiac 
T cell samples and the high frequencies found for some sequences 
(37) indicated a clonal expansion of these cells. The Gini inequality 
coefficient was further calculated as an indicator of the repertoire 
evenness and clonal dominance (Figure 6C and Supplemental Fig-
ure 6B): a Gini coefficient value of 0 denotes an even repertoire, 
in which every sequence is present in equal abundance, whereas 
a value of 1 indicates that the repertoire is dominated by a single 
sequence (38, 39). Notably, the cardiac T cells had the highest Gini 
scores among all the groups (Figure 6C, P < 0.05), which further 
indicates that the post-MI T cell responses were marked by oli-
goclonal expansions. Because the pool of T cells found in tissues 
was considerably smaller than that in LNs, we also assessed the 
Gini coefficient for a subsampling of equal size in each group (Sup-
plemental Figure 6B). The observations remained unaltered also 
under these conditions. Heart T cells also had a much less diverse 
repertoire than that found in LNs, as assessed using Simpson’s 
diversity index (Figure 6D and Supplemental Figure 6B). Most 
strikingly, T cells infiltrating the infarcted myocardium exhibited a 
unique repertoire signature, as evidenced by several factors. First, 
the MI-related cardiac TCR repertoire was marked by a partic-
ular usage of variable (TRBV) and joining (TRBJ) gene segments 
(Figure 6, E and F, and Supplemental Figure 6E). In particular,  we 
found that TRBV19 was significantly expanded in MI-related car-
diac T cells compared with its usage in the med-LNs, whereas the 
usage of TRBV5 was significantly reduced (Figure 6E, P < 0.05). 
Second, the CDR3 length distribution of TRBV19 sequences was 
skewed in the heart samples, whereas a Gaussian distribution was 
found in the LN samples (Supplemental Figure 6D). Because V-J 
recombination is a random process, the length distribution of nat-
ural repertoires tends to have a Gaussian distribution. Therefore, 
biases in the distribution of TCRβ CDR3 lengths are indicative of 
clonal expansions (40). Third, MI-related T cells had a unique pool 
of sequences exhibiting minimal overlap with all the other samples 
investigated in our study (Figure 6G and Supplemental Figure 6F).
The identity of cognate antigens could be directly extrapolated 
from the TCR sequence data. Therefore, we also assessed the TCR 
repertoire of CD4+ T cells purified from the axillary LNs (ax-LNs) 
of mice that were subcutaneously immunized with cardiac myosin 
and heart extract (in adjuvants), because these repertoires were 
expected to be enriched in heart-specific sequences upon specif-
ic immunization. As a control, we also assessed the ax-LN TCR 
repertoire in mice that received subcutaneous administration of 
the adjuvant alone. The high degree of clonality exhibited by the 
cardiac T cell pool remained statistically significant compared with 
that found for all ax-LN repertoires, even those from immunized 
mice (Supplemental Figure 7, A–E). Notably, the Th cell repertoire 
found in the ax-LNs of mice that received heart extract immuniza-
tion also showed an increased TRBV19/TRBV5 ratio, similar to that 
found for cardiac T cells and in sharp contrast to that found for the 
control ax-LNs (Supplemental Figure 7, F and G). Notwithstanding, 
the comparison of the TCRβ CDR3 sequences in the infarcted and 
immunized groups revealed no significant repertoire overlap. To a 
great extent, this result might be related to the fact that the cardiac 
T cell repertoire is largely composed of private sequences (i.e., no 
CDR3 repertoire overlap between individual cardiac EMI samples).
Taken together, the results from this unbiased screening 
approach revealed that the CD4+ T cells infiltrating the infarcted 
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are either in the heart or the med-LNs (heart-draining LNs) rather 
than in the periphery. To validate these findings, we assessed the 
presence of FOXP3+ and CD4+ cells in cardiac autopsy samples. 
Twenty-three patients were diagnosed at autopsy with having had 
a recent MI in the left ventricle. These MI patients were further 
categorized into 3 distinct reaction phases. The early phase (~3–
myocardium had a distinct T cell repertoire signature dominated 
by a limited set of expanded clones. These characteristics are hall-
marks of antigen-driven responses.
Evidence for a heart/T cell axis in MI patients. We subsequently 
sought to assess the existence of a putative heart/T cell axis in MI 
patients. Our EMI findings showed that the most important T cells 
Figure 5. Heart-specific CD4+ T 
cells activated in the MI context 
exert cardioprotective effects. 
(A) Experimental design: TCR-M 
cells (specific for the cardiac 
antigen MYCA614–629) and DO11.10 
cells (specific for the irrelevant 
antigen OVA323–339) were adoptively 
transferred into DO11.10 mice prior 
to MI or sham operation, and the 
cardiac outcomes were monitored 
at the peak of the healing phase 
(day 7). (B) The infarct size and 
long parasternal axis (apex-aortic 
valve) were assessed by echocar-
diography. The (C) FAC, (D) ESA, 
and (E) EDA at the mid-papillary 
level were assessed by echocardi-
ography. (F) Cardiac macrophages, 
defined as CD45+CD11b+Ly6G–CD64+ 
singlets, were stratified into 4 
major subsets according to CCR2 
and MHC-II expression, and the 
effects in DO11.10 versus TCR-M 
cells on each subset’s distribution 
were assessed (day 5). (G) The 
collagen area in scar tissue 5 days 
after MI in DO11.10- and TCR-M–
transferred mice was quantified by 
Picrosirius red staining (PSR). (H) 
Immunofluorescence of collagen 
III and its quantification in scar 
tissue 5 days after MI in DO11.10- 
and TCR-M–transferred mice. Scale 
bars: 100 μM. The bar graphs dis-
play the group mean values (bars), 
the SEM, and the distribution of 
each individual sample. Statistical 
significance was determined by 
2-tailed, unpaired t test. *P < 0.05 
and **P < 0.01. The data from 
TCR-M (n = 5–10) and DO11.10 (n = 
7–9) recipients were acquired in 3 
experiments.
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Several mouse studies have shown that T cells infiltrating the 
injured myocardium are activated in and originate from the med-
LNs (16, 17, 25), suggesting that assessing med-LN morphology 
and cellularity in patients with MI could also yield clinically rel-
evant information. Thus, we acquired thoracic CT images from 
MI patients to assess med-LN morphology. Moreover, we com-
bined CT with PET imaging using a radiolabeled CXCR4 ligand 
([68Ga]pentixafor). CXCR4 is a chemokine receptor that is con-
stitutively expressed at high levels on T cells and regulates their 
migration along gradients of the chemokine CXCL12 (41). CXCR4 
is also expressed on some monocyte subsets (42), on B cell sub-
sets (43), and on hematopoietic stem cells (44), which are present 
at only small frequencies within LNs. A flow cytometric analysis 
12 hours after MI) was marked by lactate dehydrogenase (LDH) 
decoloration without neutrophilic cell infiltration (n = 6). In the 
inflammatory phase (12 hours to 5 days after MI), neutrophilic 
granulocytes were particularly observed in the infarcted myocar-
dium (n = 9), whereas in the proliferation phase (5–14 days after 
MI), the formation of granulation tissue was obvious (n = 8). Nine 
patients without pathological evidence of MI-related death were 
included as controls. A description of the patients in whom car-
diac autopsies were performed is provided in Supplemental Table 
4. As shown in Figure 7, A–E, we found CD4+ and FOXP3+ cells in 
the infarcted hearts, and their expression levels peaked during the 
proliferative phase of wound healing (P < 0.05). Neither CD4+ nor 
FOXP3+ cells were found in the control hearts.
Figure 6. CD4+ T cells infiltrating the murine infarcted myocardium are clonally expanded and exhibit a unique repertoire signature. (A) Th cells from 
the heart and med-LNs of infarcted and sham-operated mice (day 7) were purified by FACS. (B) Tree maps of representative repertoires from each group. 
Each spot represents a unique TRBV-CDR3 recombination, and the size of each spot denotes its relative frequency. The unevenness of the spots indicates 
clonal expansions. (C) Repertoire evenness was assessed by the Gini coefficient. (D) Repertoire diversity was assessed on the basis of 1-Simpson’s diversity 
index. (E) Heatmap depicting the TRBV gene usage in each group. The asterisks at the top of the graph indicate a statistically significant difference (P < 
0.05) between the cardiac and LN repertoires, as determined by 2-way ANOVA followed by Tukey’s multiple comparisons test. (F) Correlation among the 
frequencies of the TRBV gene segment between any 2 given samples. (G) Heatmap showing the degree of TRBV CDR3 sequence sharing (Jaccard index) 
between any 2 given samples. The bar graphs in C and D display the group mean values (bars), the SEM of 3 to 4 samples per group, and the distribution 
of each individual value. Statistical significance for C and D was determined by 1-way ANOVA followed by Dunnett’s multiple comparisons test. *P < 0.05 
compared with all the other groups.
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Figure 7. A heart/T cell axis in MI patients. (A–E) Histological analyses of cardiac autopsy samples revealed that Th cells also accumulated in the human 
infarcted myocardium, particularly during the proliferative (wound-healing) phase. (A) Representative IHC micrographs show the presence of FOXP3+ 
(black arrows) and CD4+ (red arrows) cells in cardiac tissues. Scale bars: 50 μm. (B) LSFM showing the presence of CD3+ T cells in the infarcted human 
myocardium. Z-stack: 350 μm. (C–E) Numbers of CD4+, FOXP3+, and CD4+FOXP3+ cells/mm2 in each phase after MI (early, inflammatory, proliferative). The 
whiskers represent the percentile range, with the medians ± CIs from 6 to 9 samples per group. *P < 0.05, by nonparametric Kruskal-Wallis test corrected 
for multiple comparisons using Dunn’s test. (F–H) Transaxial slices of (F) PET and (H) fused PET/CT showing increased CXCR4 expression in med-LNs 
after MI (arrows) and in the infarcted myocardium (inset). Both the (G) med-LN sizes and (I) CXCR4 expression (as assessed by SUVs) were found to be 
increased after MI. The data are presented as box plots showing the medians, 25th–75th percentiles (boxes), and 5th–95th percentiles (whiskers) of 6 to 9 
cardiac autopsy samples, or 26 patients (PET/CT) per group. *P < 0.05, by Fisher’s exact test (C–E) and Welch’s t test (G and I).
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
4 9 3 2 jci.org   Volume 129   Number 11   November 2019
T cells reportedly influence cardiac injury, repair, and remod-
eling in various organisms, ranging from fishes to mammals 
(16, 18–21, 56). Nevertheless, the question of whether post-MI 
autoimmune responses exert salutary or detrimental effects has 
remained debated (54). Independent laboratories have recently 
reported that T cells may foster early cardiac healing by modu-
lating macrophage polarization (18), fibroblast activity (20), and 
extracellular purinergic metabolism (21). However, chronic T cell 
activation in the myocardium has also been reported to fuel the 
development of adverse remodeling in models of ischemic and 
stress overload–induced HF (19, 25–27). Moreover, the reactivity 
profile of T cells activated in the MI context has not to our knowl-
edge been assessed, and whether these cells target specific anti-
gens released by dying cardiomyocytes or simply respond to the 
inflammatory milieu remains largely unclear (57).
Here, we found that T cells infiltrating the infarcted myocar-
dium display a unique repertoire signature marked by a preferen-
tial expansion of TCRBV19-expressing clones. Notably, we also 
observed a similar bias toward the use of TRBV19 gene segments 
in mice immunized with cardiac antigens. In a previous study, Hu 
et al. (58) also observed skewed TRBV19+ T cell responses in a 
murine model of cardiac allograft transplantation. Furthermore, 
Klingenberg et al. (59), Heidecker et al. (60), and Blohm et al. (61) 
independently reported elevated TCRBV19 expression in coro-
nary thrombi obtained from patients with coronary syndrome, and 
in cardiac biopsies from patients with autoimmune myocarditis 
and dilated cardiomyopathy, respectively. Taken together, these 
findings strongly suggest that TRBV19+ T cells might be associ-
ated with heart-specific T cell responses in different organisms, 
ranging from mice to humans. The causes underlying this remark-
able association between specific TRβV usage and cardiotropic 
immune responses remain unclear, but the converging evidence 
might encourage future research that will elucidate this point.
In the present study, we identified cardiac myosin (MYHCA) 
as a dominant cardiac antigen in the MI context and established 
a defined system for dissecting the role of MYHCA-specific T cell 
responses in the wounded myocardium in unprecedented detail. 
MYHCA is a prototypical cardiac antigen for several reasons: it 
is selectively expressed in the myocardium but not in any other 
tissue (31, 62); it is constitutively processed and presented to T 
cells by cardiac antigen-presenting cells (34); in contrast to most 
tissue-restricted proteins, MYHCA is not expressed by thymic epi-
thelial cells, meaning that central tolerance to this cardiac antigen 
is absent or impaired (63); and it has been strongly implicated in 
the pathogenesis of autoimmune myocarditis (33).
In addition to specificity, our data reveal that the myocardial 
milieu dictates T cell phenotypic polarization favoring the in situ 
induction of Treg cells and the development of protective auto-
immune responses that benefit tissue repair through the promo-
tion of collagen deposition. The latter findings are in accordance 
with those obtained in our previous study, which revealed that 
mice lacking CD4+ T cells have impaired collagen deposition after 
EMI (16). The detailed mechanism underlying the T cell–mediat-
ed myocardial fibrosis process remains elusive, but our findings 
suggest that it might be dependent on crosstalk with MHC-IIhi 
CCR2lo macrophages, which are upregulated in TCR-M–transferred 
mice. Recent studies have established that MHC-IIhiCCR2lo mac-
of the CXCR4 distribution across different leukocyte subsets in 
mice confirmed that T cells accounted for more than 90% of the 
CXCR4+ cells in the med-LNs but less than 15% of the CXCR4+ 
cells in the heart (Supplemental Figure 8). We therefore used a 
noninvasive CXCR4 monitoring strategy to obtain a readout for 
T cellularity in heart-draining LNs. Patients with nonmalignant 
Conn’s adenoma who had undergone [68Ga]pentixafor PET/CT 
for a diagnostic workup were included as controls. Conn’s adeno-
mas are aldosterone-producing benign conditions that account for 
30% to 40% of all cases of primary aldosteronism. Because these 
adenomas overexpress CXCR4 (45), these patients were subjected 
to receptor-directed imaging as part of an endocrinological inves-
tigation, and none of these patients were found to have elevated 
serum levels of C-reactive protein (<0.5 mg/dL).
As shown in Figure 7, F and G, the med-LNs were significantly 
enlarged in MI patients but not in the control group patients (19.1 
± 7.6 mm versus 11.7 ± 4.2 mm; P < 0.05, measured on day 7 after 
MI, range, 2–13 days). The patients with MI also had significantly 
increased CXCR4 expression in the med-LNs compared with the 
control patients (as derived by [68Ga]pentixafor PET/CT; maxi-
mum standardized uptake value [SUVmax] of 2.7 ± 0.9 versus 1.9 
± 0.3, P < 0.001, Figure 7, G–I). These findings indicated that the 
med-LN enlargement observed in MI patients might at least in 
part be related to local expansion in the T cell compartment. Fur-
thermore, the size of the med-LNs showed a moderate correlation 
with the infarct volume derived by cardiac magnetic resonance 
imaging (CMR) (r = 0.45, P = 0.05, Supplemental Figure 9A) and 
with the levels of serum creatine kinase (CK) after MI (sum of CK, 
r = 0.57, P < 0.01, Supplemental Figure 9B). The uptake of [68Ga]
pentixafor in the med-LNs was positively correlated with CXCR4 
expression in the infarcted myocardium (r = 0.52, P = 0.03, Sup-
plemental Figure 9C). Moreover, the CXCR4 signal in the med-
LNs suggested a positive prognosis, with smaller myocardial 
necrosis volumes in a follow-up CMR imaging study (median 4 
months after MI, r = –0.51, P = 0.06, Supplemental Figure 9D). 
Taken together, these clinical findings reveal for the first time to 
our knowledge the existence of a local heart/med-LN/T cell axis 
in patients with MI and show remarkable similarities with the find-
ings in the framework of EMI.
Discussion
Emerging concepts in the field of cardiology suggest that the 
infarcted myocardium could be perceived as a wounded tissue 
(46), and hence the immunological phenomena underlying myo-
cardial repair have received considerable attention worldwide (5, 
8, 47–51). The contribution of innate immune mechanisms to post-
MI inflammation, healing, and remodeling has been well scruti-
nized over the past 2 decades (52, 53), but the involvement of the 
adaptive arm of the immune system has only recently been recog-
nized (8, 16, 18, 20, 22, 54, 55). In this study, we assessed global 
features of the post-MI T cell repertoire and pinpointed a defined 
cardiac antigen that is targeted by CD4+ T cells after EMI to dis-
sect the bidirectional cardio-immune crosstalk in unprecedented 
detail. Moreover, through a combination of histological analyses 
of cardiac tissue samples with noninvasive imaging of the med-
LNs in MI patients, we provide evidence that such a heart/T cell 
axis might hold great translational implications.
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of all lymphocytes are typically present in the peripheral blood) 
(66) and might even allow the tailoring of directed immunother-
apeutic interventions in the future.
Cardiologists can rely on good therapeutic and intervention-
al options for the treatment of acute MI and for attenuating the 
progression of remodeling (9, 10), but no tools are currently avail-
able for fostering the myocardial healing processes that bridge 
these 2 conditions. In fact, prospectively validated biomarkers are 
currently not available for monitoring the quality of ongoing myo-
cardial healing, and thus clinicians cannot identify patients under-
going adverse remodeling until they reach a critical HF stage. 
Hence, there is an unmet need in the field of cardiology to better 
understand and eventually modulate the mechanisms underlying 
the myocardial repair process (8, 67). A new discipline at the cross-
roads between immunology and cardiology has rapidly flourished 
over the past decade, with the aim of filling these gaps. From the 
cardiological perspective, this multidisciplinary enterprise might 
offer new and exciting opportunities for preventing the devel-
opment of ischemic HF, which is a consequence of poor post-MI 
healing. From an immunological perspective, this association with 
cardiology might offer a unique opportunity to better understand 
the often-neglected aspects of physiological autoimmunity.
Methods
Detailed descriptions of the experimental methods are provided in the 
Supplemental Methods.
Study design
Mouse studies. Our aim was to clarify the functional significance of 
autoreactive T cell responses to EMI. Therefore, we selected a model 
of transgenic murine cardiac myosin-specific CD4+ T cells (TCR-M) 
that were adoptively transferred into WT and DO11.10 recipient mice 
prior to the induction of EMI through permanent surgical ligation of 
the left coronary artery. The recipient DO11.10-treated mice were 
selected in some experiments because the entire CD4+ T cell compart-
ment in these animals is composed of OVA-specific cells (i.e., an irrele-
vant antigen in the MI context). The distribution and differentiation of 
endogenous and transferred T cells were analyzed by flow cytometry 
and transcriptomics of sorted cells. Echocardiography was performed 
to characterize the clinical phenotype of the animals. To further study 
the role of endogenous lymphocytes activated in the MI context, bulk 
med-LN–derived cells were adoptively transferred into naive lympho-
cyte-deficient Rag1-KO mice. Furthermore, we performed an analysis 
of the TCR repertoire using a TCR sequencing approach to confirm 
the clonal expansion of endogenous T cells in response to MI.
The echocardiographic imaging data were evaluated by a blinded 
experimenter. The exclusion criteria were set a priori according to the 
heart rate during echocardiography (heart rate >450 bpm), and the 
FACS cell yields were too low to draw reliable conclusions. Outliers 
were not excluded from the statistical analyses.
Human studies. The translational relevance of the murine findings 
obtained in the current study was tested in a clinical setting using his-
tological and imaging approaches. CD4+ and FOXP3+ T cells on immu-
nohistological slices of myocardial autopsy samples from patients who 
died at various time points after MI were quantified as previously 
described (68). Furthermore, 9 patients for whom there was no patho-
logical evidence of death from a cause related to MI were included 
rophages exhibit a transcriptome profile enriched with profibrotic 
genes, show lower metalloproteinase activity, and are involved in 
the cardiac fibrosis process in models of diastolic dysfunction (36).
It is important to consider that the role of autoreactive T cells 
in MI and HF is likely stage dependent. This is particularly rele-
vant for T cell–mediated cardiac fibrosis. Building a solid and fast 
scar after MI helps prevent cardiac rupture and infarct expan-
sion, but progressive collagen deposition can also lead to adverse 
remodeling (7). This might help explain why cardiac CD4+ T cells 
have been recently implicated in both salutary and pathogenic 
mechanisms (16–28). Furthermore, it is important to recognize 
that TCR-M cells induce autoimmune myocarditis in donor mice 
(33). Together, these findings indicate that the outcome of heart 
autoimmunity is largely context dependent and reveal an what we 
believe to be an unprecedented role for the myocardial milieu in 
the shaping of T cell phenotypic polarization.
A similar dual role for Th cells in mediating tissue-specific 
autoimmunity and repair was previously reported by Schwartz 
et al. (11). These authors observed that the same antigen-specific 
CD4+ T cells that mediate experimental autoimmune encepha-
lomyelitis can also foster spinal cord repair. Understanding the 
differences between physiological and pathogenic heart-specific 
autoimmunity might be a central issue to be scrutinized in future 
studies in this field.
To the best of our knowledge, we provide the first report of 
the existence of a heart/med-LN/T cell axis in patients with MI. 
Moderate infiltration of CD4+ and FOXP3+ cells was consistently 
observed in the infarcted myocardia of mice and humans. The 
kinetics of cardiac T cell infiltration showed substantial similari-
ties across species, and the numbers of infiltrating cardiac T cells 
peaked at the healing phase. MI patients also show alterations in 
their med-LN morphology and cellular composition that are sim-
ilar to those observed in rodents (16, 17, 24). CT measurements 
provided valuable information of the med-LN morphology but 
could also aid the discrimination of alterations due to edema from 
those due to increased cellularity. Therefore, the critical advan-
tage provided by combined CT/CXCR4 PET tracing is that this 
approach provides strong evidence for alterations due to increased 
cellularity, which is a hallmark of adaptive immune responses. We 
acknowledge that the widespread distribution of CXCR4 expres-
sion across different cell types demands careful interpretation of 
these findings. However, the limited specificity of this target can 
be compensated by the anatomical specificity of our observations, 
because lymphocytes account for the vast majority of cells within 
LNs (64). It might therefore be safe to conclude that the PET/CT 
approach used in this study could offer a suitable method for mon-
itoring local adaptive immune responses in MI patients. Indeed, 
a recently published study revealed that CXCR4 plays an import-
ant role in controlling T cell trafficking in the context of EMI and 
thereby influences the healing outcome (65), and these findings 
provide great mechanistic support for our clinical findings.
The observed correlation between alterations in the med-LNs 
and the clinical findings (e.g., infarct volume and follow-up car-
diac function) reinforces the clinical relevance of this approach 
and indicates that imaging the heart-draining LNs might provide 
additional valuable clinical information. This bold step might help 
overcome the limitations of peripheral blood sampling (only <2% 
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the German Medicinal Products Act (AMG section 13 2b) and in accor-
dance with the responsible regulatory body (Regierung von Oberfran-
ken, Bayreuth, Germany). All patients provided written informed con-
sent prior to undergoing imaging procedures. Given the retrospective 
nature of this study, the local IRB of the University Hospital Würzburg 
waived the requirement for additional approval.
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as controls. Furthermore, we reexamined existing PET/CT data sets 
from patients who had recently had a MI and from patients without 
heart disease using a novel CXCR4-specific radioligand and depict-
ed its expression in both med-LNs and the myocardium (69). Five 
patients who underwent CXCR4-directed PET/CT because of a sus-
pected benign Conn’s adenoma were included as controls. Detailed 
patient information is provided in Supplemental Tables 4 and 5.
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Statistics
Graphs of the data obtained from all the EMI studies were prepared to 
display the group mean values (bars), the SEM, and the distributions 
of each individual value. Statistical analyses were performed using 
GraphPad Prism software (version 7.0d, GraphPad Software), and 
the TCR-Seq data were statistically analyzed using MATLAB 2017a 
(MathWorks). A P value of less than 0.05 was considered statistical-
ly significant. The statistical analyses of the data obtained from the 
clinical studies were performed using Statistical Packages for Social 
Sciences software (IBM SPSS 22.0.0.0, IBM Corp.). Levene’s test for 
normality was applied and showed that the data were not normally 
distributed. Differences between groups containing continuous data 
were tested using the Mann-Whitney U test, unless otherwise indicat-
ed. Fisher’s exact test and the Freeman-Halton extension of Fisher’s 
exact test were used to test the associations between categorical data. 
An Unpaired , 2-tailed t test was used to compare the mean of 2 groups 
with data following a normal distribution. The results were considered 
significantly different if the 2-sided P value was less than 0.05. The 
data are presented as box plots showing the medians, 25th–75th percen-
tiles (boxes), and 5th–95th percentiles (whiskers).
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